Biotechnology company and drug delivery platform
innovator Lexaria Bioscience
(CSE: LXX) (OTC: LXRP) today announced its entry into a definitive
five-year agreement, via its subsidiary Lexaria Hemp Corp., to provide its
patented DehydraTECH(TM) technology to Universal Hemp LLC. Under the agreement,
Universal Hemp, a B2B manufacturer of high-performing hemp-derived bulk
ingredients to the consumer packaged goods and nutraceutical industries, will
utilize the technology in many CBD-based food ingredients to be produced and
sold across the U.S. immediately, as well as in Canada when regulations permit.
“We are very excited about signing this licensing agreement with Lexaria
Bioscience to bring to market Lexaria’s highly effective delivery system which
makes cannabidiol or hemp-derived CBD readily available in the human body,”
Universal Hemp CEO and Founder Chad Kahunahana said in the news release.
“Lexaria’s unique technology was developed over many years for specified
applications and is now, for the first time, being applied to CBD at scale and
available for general use. We anticipate our SuperBio Infusion line of
ingredients will become the industry leader for CBD-infused health and beauty,
food and beverage, wellness, athletic and other products where maximum
performance is vital. In terms of bioavailability, shelf stability and taste
this is the best performing technology in the market, hands down. Our corporate
customers cannot wait to put our water-soluble solution into their products!”
To view the full press release, visit http://ibn.fm/H5xd0
About Lexaria Bioscience Corp.
Lexaria Bioscience Corp. licenses disruptive patented
delivery technology that promotes healthier ingestion methods, lower overall
dosing and higher effectiveness of lipophilic active molecules. Lexaria has
multiple patents pending in over 40 countries around the world and has patents
granted in the USA and in Australia for utilization of its DehydraTECH(TM)
delivery technology. Lexaria’s technology provides increases in intestinal
absorption rates; more rapid delivery to the bloodstream; and important taste-masking
benefits, for orally administered bioactive molecules including cannabinoids,
vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other
molecules. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates
relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and
more, these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment